Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.14365/5469
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYau, Thomas-
dc.contributor.authorChan, Stephen Lam-
dc.contributor.authorKelley, Robin Kate-
dc.contributor.authorFinn, Richard S.-
dc.contributor.authorYoo, Changhoon-
dc.contributor.authorFuruse, Junji-
dc.contributor.authorRen, Zhenggang-
dc.date.accessioned2024-08-25T15:13:17Z-
dc.date.available2024-08-25T15:13:17Z-
dc.date.issued2024-
dc.identifier.issn0732-183X-
dc.identifier.issn1527-7755-
dc.identifier.urihttps://hdl.handle.net/20.500.14365/5469-
dc.description.sponsorshipMerck Sharp Dohme LLCen_US
dc.description.sponsorshipMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.en_US
dc.language.isoenen_US
dc.publisherLippincott williams & wilkinsen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleImpact of hepatitis B virus (HBV) infection on efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)en_US
dc.typeConference Objecten_US
dc.departmentİzmir Ekonomi Üniversitesien_US
dc.identifier.volume42en_US
dc.identifier.issue16en_US
dc.identifier.wosWOS:001275557401069en_US
dc.institutionauthor…-
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.identifier.scopusqualityQ1-
dc.identifier.wosqualityQ1-
item.grantfulltextnone-
item.openairetypeConference Object-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.cerifentitytypePublications-
Appears in Collections:WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

Page view(s)

28
checked on Nov 18, 2024

Google ScholarTM

Check





Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.